Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGynecological OncologyVisceral SurgeryDiseaseFallopian Tube CarcinomaOvarian TumorPeritoneal Carcinoma, PrimarySubgroupBRCA mutationICD10C48.-C48.1C56C57.0MeSHCarcinoma, Ovarian EpithelialFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal NeoplasmsSequenceChemotherapyChemo-substanceCisplatinOlaparibChemo-substanceCisplatinOlaparibChemo-substanceCisplatinOlaparibChemo-substanceCisplatinOlaparibNo. Substances1 RadiotherapySupportive therapySupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateNo. Substances5Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseMaintenanceTherapy intentionpalliativeRisksAnemia Hb below 8g/dlDiarrheaDyspneaElectrolyte DisturbanceEmetogenicity (MASCC/ESMO)FatigueHypomagnesemiaInfectionsNeutropeniaPainThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorMoore K / Pujade-Lauraine Evan Driel WDiseaseNeudiagnostiziertes Ovarial-Ca, Eileiter-Ca oder Peritoneal-Ca, Stadium III mit neoadjuvanter Therapie, ECOG 0-2Ovarial-Ca, Rezidiv, platinsensitiv, Zweitlinie, BRCA Mutation, ECOG 0-1OriginDepartment of Gynecology, Netherlands Cancer Institute, AmsterdamStevenson Cancer Center, University of Oklahoma, SOLO2/ENGOT-Ov21 investigatorsProtocols in Revision 2 protocols foundProtocols under revision.HIPEC - Cisplatin 100, Ovarian ca (PID108 V2.0)Olaparib 300, Ovarian ca, maintenance (PID531 V2.0)
